Lund University researchers developed a blood test intended to identify early indicators of breast-cancer recurrence by detecting circulating fragments of tumor-derived DNA. The approach is designed to flag relapse before conventional imaging or symptoms appear. If validated, the test could shift surveillance from periodic scans to earlier molecular detection, supporting earlier intervention strategies. The key next steps are prospective performance comparisons, defining clinical thresholds for action, and determining how the assay behaves across subtypes and treatment histories.